ATE540696T1 - Erbb2-antagonisten für die tumorschmerztherapie - Google Patents

Erbb2-antagonisten für die tumorschmerztherapie

Info

Publication number
ATE540696T1
ATE540696T1 AT05734984T AT05734984T ATE540696T1 AT E540696 T1 ATE540696 T1 AT E540696T1 AT 05734984 T AT05734984 T AT 05734984T AT 05734984 T AT05734984 T AT 05734984T AT E540696 T1 ATE540696 T1 AT E540696T1
Authority
AT
Austria
Prior art keywords
pain therapy
tumor pain
erbb2 antagonists
erbb2
antagonists
Prior art date
Application number
AT05734984T
Other languages
English (en)
Inventor
David B Agus
Original Assignee
David B Agus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David B Agus filed Critical David B Agus
Application granted granted Critical
Publication of ATE540696T1 publication Critical patent/ATE540696T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05734984T 2004-04-08 2005-04-07 Erbb2-antagonisten für die tumorschmerztherapie ATE540696T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56107604P 2004-04-08 2004-04-08
PCT/US2005/011781 WO2005099756A2 (en) 2004-04-08 2005-04-07 ErbB ANTAGONISTS FOR PAIN THERAPY

Publications (1)

Publication Number Publication Date
ATE540696T1 true ATE540696T1 (de) 2012-01-15

Family

ID=35150505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05734984T ATE540696T1 (de) 2004-04-08 2005-04-07 Erbb2-antagonisten für die tumorschmerztherapie

Country Status (7)

Country Link
US (2) US20060034840A1 (de)
EP (1) EP1737489B1 (de)
JP (1) JP4969440B2 (de)
AT (1) ATE540696T1 (de)
AU (1) AU2005232657B2 (de)
CA (1) CA2563341C (de)
WO (1) WO2005099756A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
PL2248899T3 (pl) * 2003-03-19 2015-10-30 Biogen Ma Inc Białko wiążące receptor nogo
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
KR101239542B1 (ko) 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
HRP20141111T1 (hr) * 2004-07-22 2015-01-02 Genentech, Inc. Sastav her2-protutijela
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
ES2710439T3 (es) 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
CA2902070A1 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
EP1965827B1 (de) 2005-12-02 2015-02-25 Biogen Idec MA Inc. Behandlung von entmyelinisierenden erkrankungen
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
EP2899541A1 (de) 2007-03-02 2015-07-29 Genentech, Inc. Voraussage der Reaktion auf einen HRE-Dimerisationshemmer auf Basis niedriger HER3-Expression
JP5674469B2 (ja) * 2007-10-11 2015-02-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法
CN101918540B (zh) * 2007-11-08 2016-05-11 比奥根Ma公司 Lingo-4拮抗剂在治疗涉及脱髓鞘的疾患中的应用
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
JP2011527572A (ja) * 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
JP2014520792A (ja) * 2011-07-06 2014-08-25 スィーケフス ソールラン ホーエフ Ｅｇｆｒ標的治療
PT4241849T (pt) 2011-10-14 2024-10-30 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
WO2013106253A1 (en) 2012-01-10 2013-07-18 Hzo Inc. Methods, apparatuses and systems for monitoring for exposure of electronic devices to moisture and reacting to exposure of electronic devices to moisture
US9146207B2 (en) 2012-01-10 2015-09-29 Hzo, Inc. Methods, apparatuses and systems for sensing exposure of electronic devices to moisture
HK1202431A1 (en) 2012-05-02 2015-10-02 Symphogen A/S Humanized pan-her antibody compositions
MX381731B (es) 2012-05-14 2025-03-13 Biogen Ma Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
AU2013362134B2 (en) * 2012-12-21 2018-07-05 Sykehuset Sorlandet Hf EGFR targeted therapy of neurological disorders and pain
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
WO2015009831A2 (en) * 2013-07-17 2015-01-22 Foundation Medicine, Inc. Methods of treating urothelial carcinomas
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
CN106163558A (zh) 2014-04-25 2016-11-23 豪夫迈·罗氏有限公司 用曲妥珠单抗‑mcc‑dm1和帕妥珠单抗治疗早期乳腺癌的方法
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
SI3302551T1 (sl) 2015-05-30 2024-10-30 F. Hoffmann-La Roche Ag Metode zdravljenja predhodno nezdravljenega her2-pozitivnega metastatskega raka dojk
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN110505880A (zh) 2016-11-04 2019-11-26 基因泰克公司 Her2阳性乳腺癌的治疗
EP3562844A1 (de) 2016-12-28 2019-11-06 Genentech, Inc. Behandlung von fortgeschrittenem her2-exprimierendem krebs
MY189536A (en) 2017-01-17 2022-02-16 Hoffmann La Roche Subcutaneous her2 antibody formulations
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
WO2020115108A1 (en) * 2018-12-06 2020-06-11 Sørlandet Sykehus Hf Egfr inhibitors and their use in the treatment of neuroathic pain
TWI807338B (zh) * 2020-06-26 2023-07-01 美商美國禮來大藥廠 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途
EP4171748A1 (de) 2020-06-29 2023-05-03 Genentech, Inc. Kombination aus pertuzumab und trastuzumab mit fester dosis
TWI859538B (zh) * 2021-05-21 2024-10-21 美商美國禮來大藥廠 靶向表皮調節素(epiregulin)之化合物及方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5824311A (en) * 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2120745A1 (en) 1992-06-30 1994-01-06 Philip G. Kasprzyk A combination of anti-erbb-2 monoclonal antibodies and method of using
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
ATE186219T1 (de) 1993-03-24 1999-11-15 Berlex Biosciences Kombination von antihormonale und bindende moleküle zur krebsbehandlung
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
DK0659439T3 (da) 1993-12-24 2002-01-14 Merck Patent Gmbh Immunkonjugater
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US20020002276A1 (en) 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US7041292B1 (en) * 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
JP4579471B2 (ja) 1999-06-25 2010-11-10 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
WO2004048525A2 (en) * 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies

Also Published As

Publication number Publication date
EP1737489B1 (de) 2012-01-11
EP1737489A2 (de) 2007-01-03
US20110064737A1 (en) 2011-03-17
AU2005232657A1 (en) 2005-10-27
CA2563341A1 (en) 2005-10-27
US8333964B2 (en) 2012-12-18
JP2007532566A (ja) 2007-11-15
AU2005232657B2 (en) 2010-12-16
WO2005099756A3 (en) 2006-06-15
US20060034840A1 (en) 2006-02-16
WO2005099756A2 (en) 2005-10-27
JP4969440B2 (ja) 2012-07-04
CA2563341C (en) 2014-10-21

Similar Documents

Publication Publication Date Title
WO2005099756A3 (en) ErbB ANTAGONISTS FOR PAIN THERAPY
AU2018275359A1 (en) Antibodies specific for FLT3 and their uses
ZA200701656B (en) Humanized anti-cment antagonists
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
IL258880A (en) Diarylhydantoin compounds
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
TW200420565A (en) C-6 modified indazolylpyrrolotriazines
GEP20074252B (en) Antibodies to vla-1
PT2100614E (pt) Antagonistas de receptor para tratamento de cancro ósseo metastático
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
DK1951759T3 (da) Anti-EGFR-antistoffer
AR075896A1 (es) Anticuerpos anti-her (factor de crecimiento epidermico)
IL181473A0 (en) Humanized anti-beta 7 antagonists and uses therefor
BG108495A (en) 5-ht receptor ligands and uses thereof
MX343227B (es) Anticuerpos anti-erbb3.
CY1112953T1 (el) Χρηση των αντι-cd100 αντισωματων
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
MX2010005966A (es) Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
MXPA04004492A (es) Indazolilpirrolotriazinas c-5 modificadas.
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
WO2005065266A3 (en) Di-substituted pyrrolotriazine compounds
TW200624426A (en) BACE inhibitors
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения